Pulmatrix Inc - ESG Rating & Company Profile powered by AI
The ESG score covers 17 UN Sustainable Development Goals including: 'Good Health & Wellbeing', 'Decent Work & Economic Growth' and 'Life on Land'. Detailed Sustainability assessment of Pulmatrix Inc can be accessed by logging in. This analysis of Pulmatrix Inc incorporates intelligence from across the web as well as from available filings by Pulmatrix Inc.
Pulmatrix Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.8; made up of an environmental score of 2.7, social score of 4.8 and governance score of 4.0.
3.8
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| ... | ... | ... | |
| 1476 | Philogen SpA | 3.9 | Medium |
| 1476 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | 3.9 | Medium |
| 1512 | Pulmatrix Inc | 3.8 | Medium |
| 1512 | Ampio Pharmaceuticals Inc | 3.8 | Medium |
| 1512 | Abeona Therapeutics Inc | 3.8 | Medium |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Pulmatrix Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Pulmatrix Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Pulmatrix Inc report the average age of the workforce?
Sign up for free to unlockDoes Pulmatrix Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Pulmatrix Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Pulmatrix Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Pulmatrix Inc offer flexible work?
Sign up for free to unlockDoes Pulmatrix Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Pulmatrix Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Pulmatrix Inc conduct supply chain audits?
Sign up for free to unlockDoes Pulmatrix Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Pulmatrix Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Pulmatrix Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Pulmatrix Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Pulmatrix Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Pulmatrix Inc disclose water use targets?
Sign up for free to unlockDoes Pulmatrix Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Pulmatrix Inc have a product recall in the last two years?
Sign up for free to unlockDoes Pulmatrix Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Pulmatrix Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Pulmatrix Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Pulmatrix Inc disclose parental leave metrics?
Sign up for free to unlockDoes Pulmatrix Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Pulmatrix Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Pulmatrix Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Pulmatrix Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Pulmatrix Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Pulmatrix Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Pulmatrix Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Pulmatrix Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Pulmatrix Inc disclose its waste policy?
Sign up for free to unlockDoes Pulmatrix Inc report according to TCFD requirements?
Sign up for free to unlockDoes Pulmatrix Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Pulmatrix Inc disclose energy use targets?
Sign up for free to unlockDoes Pulmatrix Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Pulmatrix Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Pulmatrix Inc
These potential risks are based on the size, segment and geographies of the company.
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.